Background: Some hormones measured in pregnancy are linked to certain hormone-sensitive cancers. We investigated whether routine serum screening in pregnancy is associated with a woman's subsequent risk of hormone-sensitive cancer.
collected in the second trimester at 15 weeks þ 0 days of gestation (ie, 15 þ0 ) to 20 weeks þ 6 days of gestation (ie, 20 þ6 ), included maternal serum AFP, total hCG, and unconjugated estriol (uE3). Around the year 2000, DIA was added to second trimester screening, and measurement of serum PAPP-A at 11 þ0 to 13 þ6 weeks was further added.
The current study examined whether abnormal prenatal concentrations of AFP, hCG, uE3, PAPP-A, or DIA were associated with an increased long-term risk of hormone-sensitive cancer.
Methods

Study Design and Data Sources
This population-based cohort study used administrative health-care datasets for the province of Ontario, Canada, where universal health care includes free prenatal screening. Prenatal biochemical screening records from seven regional laboratories (reduced to 5 as of 2007) were aggregated in the Ontario Maternal Multiple Marker Screening Database, 1993-2011. Datasets were linked using unique encoded identifiers and analyzed at Institute for Clinical Evaluative Sciences (ICES). Specifics about the ICES databases are provided in Supplementary Table 1 (available online) and described elsewhere (12) (13) (14) . The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a Research Ethics Board.
Participants
Eligible females were aged 12-55 years, with prenatal serum screening done at 11-20 completed weeks' gestation between 1993 and 2011. All pregnancies were eligible regardless of the outcome, including live births or stillbirths at 21 þ0 weeks or later gestation, miscarriages and ectopic pregnancies at less than 21 þ0 weeks' gestation, and induced abortions at any gestation. There were 1 380 840 initially eligible pregnancies ( Figure 1 ). Of these, 430 984 pregnancies (31.2%) were excluded. Exclusions were predominantly due to having fewer than 5 years of provincial health insurance plan eligibility preceding time zero, which was necessary to ensure exclusion of women with preexisting cancer (Figure 1 ). The remaining 950 259 pregnancies had a measured AFP, hCG, uE3, PAPP-A, or DIA to form the screened cohort. To simplify the analyses, we randomly selected one pregnancy per woman as the index pregnancy (n ¼ 677 247). Pregnancies lacking a serum AFP, hCG, uE3, PAPP-A, or DIA comprised the nonscreened cohort (n ¼ 972 326). These pregnancies were analyzed in a supplementary manner as outlined below.
Exposures and Outcomes
The study exposure was each prenatal biochemical screening analyte-AFP, hCG, uE3, PAPP-A, and DIA-expressed as a multiple of the median (MoM) (Supplementary Table 1 , available online). For each analyte, the MoM value was originally calculated at each respective laboratory by dividing the marker concentration of a woman by the normal median for women of the same gestational age. The MoM metric is commonly used in clinical reporting that standardizes test results between different laboratories, thus eliminating interlaboratory variation.
The primary outcome was the occurrence of each hormonesensitive cancer-breast, ovarian, endometrial, and thyroid-diagnosed from at least 21 þ0 weeks' gestation ("time zero") and 
Statistical Analysis
The association between each analyte (in MoM) and the log hazard of each cancer was explored using univariate fractional polynomial regression (15, 16) . Best-fitting plots were generated based on all prenatal screening results except for those resulting in a live birth or stillbirth affected by a congenital or chromosomal anomaly, or outliers of MoM beyond the 0.2nd or 99.8th percentiles (17, 18) (Supplementary Figure 1 , available online). Inspection of each individual plot enabled us to identify whether the risk of each type of cancer was more pronounced at a low or high concentration of each analyte: for AFP, this was the 5th or less percentile MoM; for hCG and DIA, it was the fifth or less MoM for breast and thyroid cancers, and greater than 95th percentile for ovarian and endometrial cancers; for uE3, it was the fifth or less percentile MoM for ovarian cancer and greater than the 95th percentile for the other cancers; for PAPP-A, it was the 5th or less percentile MoM for breast, endometrial, and thyroid cancer, and greater than the 95th percentile for ovarian cancer. The main model assessed each cancer outcome in association with a potentially harmful MoM cutpoint of each analyte vs normal (referent) using multivariable Cox regression models to generate a hazard ratio (HR) and 95% confidence interval (CI) for each cancer outcome, with time-on-study as the time scale. Hazard ratios were adjusted for maternal characteristics measured at the time of the prenatal biochemical screening, including age (continuous), parity (0, 1, unknown), neighborhood income quintile (1, 2, 3, 4, 5, unknown), rural residence (rural, urban, unknown), ethnicity (Asian, black, Caucasian, other, unknown), gestational age (continuous), and year (continuous) as well as diabetes mellitus, chronic kidney disease, and illicit drug or tobacco use within 365 days preceding the 21 þ0 gestational week of pregnancy (ie, preceding "time zero").
In stratified analyses of the main model, each analyte was then reevaluated in the copresence of characteristics measured at the time of the prenatal screening that might influence a biochemical analyte and/or a woman's cancer risk, including: 1) advanced maternal age 35 years or younger, and 2) nulliparity; as well as characteristics measured at the time of a live birth or stillbirth, including; 3) a maternal placental syndrome-preeclampsia, gestational hypertension, or placental abruption or infarction; and 4) a recognized chromosomal or congenital anomaly; and 5) fetal growth restriction at the time of live birth; and 6) a pregnancy ending with a non-live birth.
Additional analyses 1-7 (Supplementary Methods, available online) considered the possible effects of maternal weight, infant feeding, previous analyte abnormalities, more extreme levels of less than or equal to the first and greater than 99th percentiles MoM, re-setting time zero to 365 days after the index delivery in case the abnormal prenatal screening result was due to an undetected cancer, more refined categories of quintile MoM, and to characterize women who did and did not undergo prenatal serum screening.
Statistical significance was set at P less than .05 without correction for multiple comparisons. All statistical analyses were performed using SAS version 9.4 for UNIX (SAS Institute Inc). All tests were two-sided.
Results
Among the 677 247 randomly selected pregnancies included in the analysis, AFP was the most frequently measured analyte (633 330 pregnancies), and DIA was the least frequent (73 768 pregnancies) due to its introduction in later years ( Table 1) Of 677 247 pregnancies in the randomly selected screened cohort, 7231 (1.07%) women were subsequently diagnosed with breast cancer, 515 (0.08%) with ovarian cancer, 508 (0.08%) with endometrial cancer, and 4105 (0.61%) with thyroid cancer. The mean (SD) age a diagnosis of cancer was 43.0 (6.0) years for cancer of the breast, 42.0 (7.1) years for ovarian, 45.4 (6.6) years for endometrial, and 39.4 (6.4) years for thyroid.
In the main model, for the outcome of breast cancer, women with an abnormally low serum PAPP-A had an increased rate compared with women whose concentration was the 5th percentile or higher (8.9 vs 7.5 per 10 000 person-years), although the risk was no longer statistically significant after adjusting for covariates (adjusted hazard ratio [aHR] ¼ 1.19, 95% CI ¼ 0.98 to 1.36) (Figure 2A ). The risk of ovarian cancer was not associated with any of the abnormal analytes. Women with abnormally high hCG greater than the 95th percentile had an increased rate of endometrial cancer compared with those below that cutpoint (0.9 vs 0.6 per 10 000 person-years) (aHR ¼ 1.98, 95% CI ¼ 1.33 to 2.95) ( Figure 2B ). The rate of thyroid cancer was increased in women with an abnormally low AFP relative to those whose AFP was above the 5th percentile (5.7 vs 4.7 per 10 000 personyears) (aHR ¼ 1.21, 95% CI ¼ 1.07 to 1.38). Additionally, women with abnormally low DIA had a marginally greater risk of thyroid cancer compared with other women (6.7 vs 4.6 per 10 000 person-years) (aHR ¼ 1.50, 95% CI ¼ 1.00 to 2.26).
The rate of breast cancer did not vary by the presence or absence of each abnormal analyte among women aged 35 years or older or among those younger than 35 years, although an effect of older age in the index pregnancy was observed ( Figure 3A ). Compared with parous women with a normal level of each analyte, nulliparous women had a decreased crude rate of breast Figure 3A ). Women with a maternal placental syndrome had a reduced associated risk of breast cancer, particularly those with normal uE3 ( Figure 3A ). The risk of breast cancer was also reduced in women with fetal growth restriction and a normal AFP, HCG, or uE3 ( Figure 3B ). For ovarian cancer, the risk was usually greatest in the copresence of an abnormal analyte and advanced maternal age at the time of prenatal screening, except for an abnormally high PAPP-A, which conferred a greater risk among those aged younger than 35 years (aHR ¼ 2.14, 95% CI ¼ 1.03 to 4.45) (Figure 4 ). Nulliparous women with a high PAPP-A also displayed a greater risk of ovarian cancer (aHR ¼ 2.33, 95% CI ¼ 1.06 to 5.09) as did those whose AFP was normal in conjunction with a child affected by congenital or chromosomal anomaly (aHR ¼ 1.48, 95% CI ¼ 1.02 to 2.14).
The risk of endometrial cancer was not statistically significantly altered in the co-presence of an abnormal analyte and each co-factor when contrasted to that observed for the abnormal analyte or the cofactor in isolation ( Figure 5 ). Even so, women with a maternal placental syndrome and abnormally high hCG had an aHR of 3.72 (95% CI ¼ 1.53 to 9.03).
For thyroid cancer, the risk was noteworthy in the copresence of abnormally low hCG and advanced maternal age relative to those with neither (aHR ¼ 1.68, 95% CI ¼ 1.29 to 2.20) (Figure 6 ). aHRs in the main model did not differ after adjusting for maternal weight, infant breastfeeding, or the presence of an abnormal prenatal screening result in a previous pregnancy (additional analyses 1-3, data not shown). At more extreme cutpoints set at less than or equal to the first or greater than the 99th percentile MoM to define each abnormal analyte, none of the adjusted models indicated a statistically significantly increased risk of cancer (additional analysis 4; Supplementary  Figure 2 , available online). Resetting time zero to start at 365 days after the index delivery did not change the previously noted increased risk of endometrial cancer with high hCG or of thyroid cancer with low AFP (additional analysis 5; Supplementary Figure 3 , available online). An incremental increase in the risk for breast cancer was seen with decreasing quintile MoM of PAPP-A (quintile 1 vs 5: aHR ¼ 1.29, 95% CI ¼ 1.13 to 1.47) and was also greater among those in the lowest three quintiles of AFP and hCG (additional analysis 6; Supplementary Figure 4 , available online).
There was a total of 950 259 biochemically screened pregnancies and 972 326 nonscreened pregnancies (additional analysis 7; Supplementary Table 2, available online). The risk of breast cancer (aHR ¼ 1.12, 95% CI ¼ 1.09 to 1.15) and thyroid cancer (aHR 1.25, 95% CI ¼ 1.20 to 1.30) was greater in the screened cohort than the nonscreened cohort (Supplementary Table 2 , available online). In contrast, the risk of endometrial cancer was decreased in the screened cohort (aHR ¼ 0.89, 95% CI ¼ 0.80 to 0.99). 
Discussion
Variation was observed in the risk of breast, ovarian, endometrial, and thyroid cancer in relation to five different prenatal serum screening analytes. About one-half of pregnancies during the study period had prenatal biochemical screening, which was available within a universal health-care setting. This 50% rate of uptake may be partly explained by our inclusion of pregnancies ending before 20 weeks' gestation. Though the characteristics of the screened pregnancies differed minimally from the unscreened pregnancies, the uptake of prenatal screening was lower for rural than urban women (Supplementary Table 2 , available online). This is consistent with previous reports (19, 20) . Also, rates of future breast and thyroid cancer were somewhat increased in unscreened pregnancies (Supplementary Table 2 , available (red circles) hazard ratios, the latter adjusted for maternal age, parity, income quintile, rural residence, ethnicity, gestational age, and year-each at the time of prenatal biochemical screening-as well as diabetes mellitus, chronic kidney disease, and illicit drug or tobacco use within 1 year before 21 þ0 weeks' gestation. Censoring was on death, end of Ontario Health Insurance Plan eligibility, or arrival at the end of study as well as bilateral mastectomy (for breast cancer), bilateral oophorectomy (for ovarian cancer), hysterectomy (for endometrial cancer), and thyroidectomy (for thyroid cancer). AFP, alpha-fetoprotein; hCG, total human chorionic gonadotropin; uE3, unconjugated estriol; DIA, dimeric inhibin A; PAPP-A, pregnancy-associated plasma protein A.
online). Cancer outcomes were identified from the Ontario Cancer Registry, which captures with a sensitivity of 98% all new cases of cancer in the entire province (21) . The relation between a screening analyte and breast cancer may have differed by cancer stage or hormone receptor status, but these data were incomplete for most of the study period. Other potential confounders were considered herein, including age, parity, placental dysfunction, diabetes mellitus, fetal growth, and non-live birth pregnancy (22) (23) (24) . We also considered breastfeeding status at hospital discharge and maternal weight (22) . Unknown were menopausal status, oral contraceptive use, and hormone use after menopause. Consistent with some previous studies, we found that the risk of breast cancer was lowest at the highest levels of maternal serum AFP (24, 25) and hCG (26, 27) . The protective effect of AFP is presumably related to its antiestrogen properties (28) , and hCG plays a role in cell proliferation and DNA repair (29). We did not find an association between second trimester uE3 and breast cancer, consistent with one other study (5) . However, high third trimester E3 has been found protective of breast cancer (30) , possibly by reducing accumulation of E1 and E2 by-products, which are carcinogenic (31) . We found that lower levels of first trimester PAPP-A conferred a higher risk of breast cancer in the long term. This appears to contradict recent studies showing that PAPP-A outside of pregnancy is overexpressed in breast and other cancers, and high PAPP-A promotes tumor growth and invasion (32) . We are unaware, however, of any study that has examined maternal serum PAPP-A and future cancer. Maternal placental syndrome was associated with a decreased risk of breast cancer, in line with one prior study (33) but not with another (34).
We did not find a statistically significant association between any of the hormones in this study and ovarian cancer. Maternal serum levels of certain sex steroids have been associated with a long-term risk of ovarian cancer (7, 8) , but little is known about other maternal hormones and ovarian cancer risk. Although inhibin (35) and PAPP-A (32) may have some utility as biomarkers of some forms of ovarian cancer, their role in the pathogenesis of ovarian cancer is unknown.
Estriol was not associated with endometrial cancer in the current study. This discrepancy may be explained by varying levels of carcinogenicity between different estrogen types (30) . High serum hCG conferred a greater risk of endometrial cancer in the current study. Although the predictive value of maternal serum hCG in the long-term risk of endometrial cancer has not been widely explored, studies in women undergoing fertility treatment suggest an association between high hCG concentrations and uterine cancer (36) . High hCG is also a biomarker for endometrial cancer and gestational trophoblastic disease. Even so, gestational trophoblastic disease or endometrial cancer at the time of biochemical screening could not have accounted for our current findings, because the additional analysis excluding women with cancer up to 365 days after the index delivery showed a persistent greater risk of endometrial cancer with high hCG. Additionally, though rare, the joint presence of a maternal placental syndrome and abnormally high hCG was associated with a markedly greater risk of endometrial cancer. This finding is, however, inconsistent with findings from a Swedish cohort study (37) and a Danish case-control study (38) . Interestingly, the latter group did report a greater risk of endometrial cancer in association with early-onset preeclampsia at 22-33 weeks' gestation (38) . Although we are unaware of other studies on pregnancy hormones and long-term risk of maternal thyroid cancer, there is some evidence of a greater risk of thyroid carcinoma in women who had hyperemesis gravidarum, thought to be related to abnormally high levels of hCG (39) .
Although the main purpose of prenatal biochemical screening has been to screen for fetal chromosomal and congenital anomalies, serum screening is also predictive of adverse pregnancy outcomes, such as preeclampsia, small-for-gestational age birthweight, and fetal death (18, 23, 40, 41) . As found herein, women with abnormal levels of hCG, AFP, or PAPP-A in early pregnancy also displayed some heightened future risk of certain types of hormone-sensitive cancers. Though appealing as a concept, the evidence to date does not support the use of prenatal serum screening to predict future cancer, and the biological mechanisms underlying these associations are not fully understood. Furthermore, whether these associations are reflective of the pregnancy state, or a perpetuated state of hormone dysregulation extending outside of pregnancy, remains to be determined.
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